Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.
Qiagen inks $225M single-cell buyout as CEO prepares to step down
Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.